Table 2.
Baseline Patient-Reported Outcomes and Symptoms by Endocrine Therapy Group
| Outcome or symptom | Mean (SD) Score | P* | |||
|---|---|---|---|---|---|
| Total (N = 186) | No Endocrine Therapy at T2 (n = 60) | Tamoxifen Initiated by T2 (n = 66) | Aromatase Inhibitor Initiated by T2 (n = 60) | ||
| SF-36 | |||||
| PCS | 45.4 (9.3) | 45.6 (9.6) | 46.3 (8.0) | 44.1 (10.4) | .41 |
| MCS | 49.4 (9.1) | 50.2 (8.4) | 48.6 (10.0) | 49.7 (8.9) | .58 |
| MFSI total | 11.1 (19.2) | 10.2 (19.9) | 11.9 (17.5) | 11.0 (20.4) | .88 |
| PSQI | 7.6 (3.6) | 7.6 (4.0) | 7.4 (3.6) | 7.9 (3.0) | .68 |
| BDI-II | 8.8 (6.8) | 9.0 (7.1) | 8.8 (6.6) | 8.5 (7.0) | .93 |
| BCPT symptom scale | |||||
| Hot flashes | 1.1 (1.1) | 0.8 (1.1) | 1.2 (1.2) | 1.3 (1.1) | .11 |
| Nausea | 0.2 (0.3) | 0.1 (0.3) | 0.2 (0.3) | 0.2 (0.3) | .90 |
| Bladder control problems | 0.3 (0.5) | 0.4 (0.6) | 0.2 (0.4) | 0.4 (0.6) | .05 |
| Vaginal problem | 0.9 (1.2) | 0.7 (0.9) | 0.8 (1.2) | 1.1 (1.3) | .11 |
| Musculoskeletal pain | 1.2 (0.9) | 1.3 (1.0) | 1.1 (0.9) | 1.4 (0.9) | .10 |
| Cognitive problems | 1.3 (1.0) | 1.1 (0.9) | 1.3 (0.9) | 1.4 (1.0) | .39 |
| Weight problems | 1.1 (1.0) | 1.2 (1.1) | 1.0 (0.7) | 1.2 (1.0) | .25 |
| Arm movement problems | 0.5 (0.7) | 0.5 (0.6) | 0.5 (0.7) | 0.4 (0.7) | .83 |
Abbreviations: BCPT, Breast Cancer Prevention Trial; BDI-II, Beck Depression Inventory II; MCS, mental component scale; MFSI, Multidimensional Fatigue Symptom Inventory; PCS, physical component scale; PSQI, Pittsburgh Sleep Quality Index; SF-36, 36-question short-form health survey; T2, 6-month follow-up time point.
*
P values are from an analysis of variance. P values ≤ .05 are statistically significant.